Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Axsome Therapeutics (AXSM) EBT: 2022-2025

Historic EBT for Axsome Therapeutics (AXSM) over the last 4 years, with Sep 2025 value amounting to -$47.2 million.

  • Axsome Therapeutics' EBT rose 26.89% to -$47.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$230.4 million, marking a year-over-year increase of 25.98%. This contributed to the annual value of -$287.1 million for FY2024, which is 20.50% down from last year.
  • As of Q3 2025, Axsome Therapeutics' EBT stood at -$47.2 million, which was up 3.48% from -$48.9 million recorded in Q2 2025.
  • Axsome Therapeutics' EBT's 5-year high stood at -$8.6 million during Q1 2023, with a 5-year trough of -$99.0 million in Q4 2023.
  • In the last 3 years, Axsome Therapeutics' EBT had a median value of -$64.6 million in 2024 and averaged -$61.9 million.
  • Per our database at Business Quant, Axsome Therapeutics' EBT soared by 78.20% in 2023 and then tumbled by 691.35% in 2024.
  • Axsome Therapeutics' EBT (Quarterly) stood at -$61.2 million in 2022, then slumped by 61.62% to -$99.0 million in 2023, then rose by 24.40% to -$74.8 million in 2024, then climbed by 26.89% to -$47.2 million in 2025.
  • Its last three reported values are -$47.2 million in Q3 2025, -$48.9 million for Q2 2025, and -$59.4 million during Q1 2025.